Answers are grounded in this paper and cite their sources.
Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.
No takes yet. Share an insight, caveat, or question.
Dickey et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: